Tag Archives: CROs

Doctors, Data, and Drug Development

It is estimated that applying big data strategies could potentially generate up to $100 billion in value annually across the US healthcare systems, specifically by optimizing innovation and improving the efficiency of research and clinical trials. With the advent of global CROs entering into the capital intensive sector of healthcare reimbursements, supporting pharmaceutical and biotech […]
Posted in R&D, Technology | Also tagged , | Leave a comment

CRO M&As Show No Sign of Slowing Down

By Lisa Henderson. With all of the activity in CRO M&As the past three years, it’s slightly amazing that it continues — and that analysts don’t see it slowing down. In fact, investment analysts speaking to the Partnerships in Clinical Trials event this month believe that from a Wall Street perspective, the publicly-traded CROs are […]
Posted in Deals, Guest Blog, Strategy | Also tagged , , , | Leave a comment

Drug Discovery CRO Sector to Thrive in Europe

The European pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery, writes Faiz Kermani. The European pharmaceutical industry accounts for nearly 40% of the global industry’s R&D investment. Although  companies are responding to current pressures by closing R&D sites, they still need to support their ongoing drug-development projects […]
Posted in Europe, Events, Global, Guest Blog, R&D | Also tagged , , | Leave a comment

Risk-Based Monitoring: From the Road Less Traveled to Productivity Superhighway

Risk-Based Monitoring:  From the Road Less Traveled to Productivity Superhighway By:  Mukhtar Ahmed, global vice president, life sciences strategy, Oracle Health Sciences The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.  Clinical trials cost 60% more today than they did just […]
Posted in Guest Blog, R&D, Regulatory, Technology | Also tagged , , , , , , | Leave a comment

Big Pharma's Second Life

Can big pharma solve its fixed cost problem by going virtual? Not entirely, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at a CBI event in The Triangle. The problem with overbearing project mangers on the sponsor side of […]
Posted in Biotech, People, R&D, Strategy, Supply Chain | Also tagged , , , , | Leave a comment
  • Categories

  • Meta